Unbound MEDLINE

Evaluation of treatment results and prognostic factors in early-stage cervical carcinoma patients treated with postoperative radiotherapy or radiochemotherapy.

Abstract

PURPOSE
To investigate the clinical features, prognostic factors, and treatment outcome in early-stage cervical carcinoma patients treated with postoperative radiotherapy (RT)/radiochemotherapy (RCT).
METHODS
The records of 256 Stage IB and II cervical cancer patients treated with postoperative RT/RCT from 1992-2007 were retrospectively reviewed. Median age of the patients was 47 (range: 25-78). Two hundred one (78.6%) patients had squamous cell carcinoma and 29 (11.3%) had adenocarcinoma. One hundred and eighty-seven (73.0%) had FIGO Stage IB and 69 (27%) had Stage II disease. Concomitant cisplatin-based chemotherapy was administered to 47 (18.4%) patients. Metastatic lymph node ratio (MLNR), defined as number of metastatic lymph nodes divided by the number of dissected lymph nodes, was 0 in 142 (55.5%) patients, from 1% to 10% in 27 (10.5%) and > 10% in 31 (12.1%) patients.
RESULTS
Median follow-up duration was 60.5 months (range: 6-202 months). Five-year locoregional control (LRC), disease-free survival (DFS), disease specific survival (DSS) and overall survival (OS) rates were 90.8%, 83.4%, 91.2%, and 85%, respectively. In multivariate analysis; bulky tumor (> 4 cm) was shown as an important prognostic factor for LRC, DFS and DSS. Pretreatment hemoglobin level (< 10 g/dl) was associated with lower OS rate. Endometrial involvement was associated with lower LRC and DFS. Treatment break > 14 days showed significance for DFS and DSS. MLNR was found as a valuable prognostic factor for all endpoints (LRC, DFS, DSS and OS). The rate of grade 3-4 late toxicity was 3.6% and 2%, respectively.
CONCLUSION
Postoperative RT/RCT is an effective treatment modality for early-stage cervical cancer patients with unfavorable features and provides satisfactory local control and survival rates with low morbidity.

Authors

Demirci S, Ozsaran Z, Ozsaran A, Yavas F, Demircioglu B, Hanhan M, Dikmen Y, Aras AB

Source

European journal of gynaecological oncology 33:1 2012 pg 62-7

MeSH

Adenocarcinoma
Adult
Aged
Antineoplastic Agents
Brachytherapy
Carcinoma, Squamous Cell
Chemoradiotherapy, Adjuvant
Cisplatin
Disease-Free Survival
Endometrium
Female
Follow-Up Studies
Hemoglobins
Humans
Kaplan-Meier Estimate
Lymphatic Metastasis
Middle Aged
Multivariate Analysis
Neoplasm Staging
Prognosis
Proportional Hazards Models
Radiotherapy, Adjuvant
Retrospective Studies
Uterine Cervical Neoplasms

Pub Type(s)

Journal Article

Language

eng

PubMed ID

22439408